Eli Lilly And's Revenue in the fiscal year 2025 $ 65,179.00 millions
Eli Lilly And's Revenue in the fiscal year 2024 $ 45,042.70 millions
Eli Lilly And's Revenue in the fiscal year 2023 $ 34,124.10 millions
Eli Lilly And's Revenue in the fiscal year 2022 $ 28,541.40 millions
Eli Lilly And's Revenue in the fiscal year 2021 $ 28,318.40 millions
LLY Revenue third quarter 2026 Y/Y Growth Comment
Eli Lilly And Company achieved in the third quarter 2026, above Company average Revenue growth of 38.61% year on year, to $ 24,397.00 millions.
Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 64 other companies have achieved higher Revenue growth. While Eli Lilly And Company' s Revenue rise of 38.61% ranks overall at the positon no. 604 in the third quarter 2026.
Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026
Eli Lilly And's Q/Q Revenue Growth
Revenue Q/Q Growth Statistics
High
Average
Low
29.6 %
2.63 %
-21.62 %
LLY's III. Quarter Q/Q Revenue Comment
Eli Lilly And Company achieved in the III. Quarter 2026 above company average sequential Revenue increase of 6.19%, to $ 24,397.00 millions, from $22,974.00 millions in the second quarter.
Within Major Pharmaceutical Preparations industry 66 other companies have achieved higher Revenue quarter on quarter growth. While Eli Lilly And's Revenue growth quarter on quarter, overall rank is 1072.
Eli Lilly And Company achieved in the III. Quarter 2026 above company average sequential Revenue increase of 6.19%, to $ 24,397.00 millions, from $22,974.00 millions in the second quarter.
Within Major Pharmaceutical Preparations industry 66 other companies have achieved higher Revenue quarter on quarter growth. While Eli Lilly And's Revenue growth quarter on quarter, overall rank is 1072.
Eli Lilly And's 12 Months Revenue Growth Year on Year
Assuming the Eli Lilly And's fiscal year would have ended in Sep 30 2026, Eli Lilly And would have reprted above average annual Revenue growth of 45.51% year on year, of $ 86,462 millions. This marks a slow-down of the companys growth trends and from the 49.58% increase in Jun 30 2026.
In the Healthcare sector 96 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 377, from total ranking in previous quarter at 485.
Assuming the Eli Lilly And's fiscal year would have ended in Sep 30 2026, Eli Lilly And would have reprted above average annual Revenue growth of 45.51% year on year, of $ 86,462 millions. This marks a slow-down of the companys growth trends and from the 49.58% increase in Jun 30 2026.
In the Healthcare sector 96 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 377, from total ranking in previous quarter at 485.
About Eli Lilly And Revenue Growth Rates (LLY), Current and Historic Growth - CSIMarket Analysis
How we calculate this
This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years).
Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
66.74%